The reproductive health therapy developer, which has raised more than $93m from backers including Novo and Merck Group, has set the terms for its initial public offering.
ObsEva, a Switzerland-based women’s reproductive health therapy developer backed by pharmaceutical companies Novo and Merck Group, set the range yesterday for an initial public offering up to $103.2m in size.
The company plans to issue 6.45 million shares on Nasdaq priced between $14 and $16 each, equating to proceeds of $96.8m if it floats at the middle of its range.
Founded in 2012, ObsEva is developing treatments for reproductive health conditions such as endometriosis and uterine fibroids, as well as…
